aTyr Pharma Past Earnings Performance

Past criteria checks 0/6

aTyr Pharma's earnings have been declining at an average annual rate of -24.6%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 6.8% per year.

Key information

-24.6%

Earnings growth rate

40.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-6.8%
Return on equity-98.0%
Net Margin-27,155.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Sep 09

We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

Jul 13
We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Feb 03
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Oct 04
Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

May 06
Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Jan 04
We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

Sep 29

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

Sep 13

aTyr Pharma gains with FDA Fast Track status for lead asset

Aug 11

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

May 10
We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Jan 24
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Dec 28

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Sep 24

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Sep 23
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

May 22
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 25
aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

Feb 09
Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan

Jan 14

ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study

Jan 04

aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study

Dec 21

aTyr Pharma (LIFE) Investor Presentation - Slideshow

Oct 31

Revenue & Expenses Breakdown

How aTyr Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:ATYR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-64130
30 Jun 241-58130
31 Mar 241-54130
31 Dec 230-50130
30 Sep 2311-43130
30 Jun 2310-45140
31 Mar 2310-45140
31 Dec 2210-45140
30 Sep 220-46130
30 Jun 220-41120
31 Mar 220-39120
31 Dec 210-34110
30 Sep 212-30100
30 Jun 212-29100
31 Mar 212-2590
31 Dec 2010-1690
30 Sep 209-1790
30 Jun 209-1690
31 Mar 208-1690
31 Dec 190-2490
30 Sep 190-2490
30 Jun 190-25100
31 Mar 190-3011-6
31 Dec 180-35120
30 Sep 180-40165
30 Jun 180-441712
31 Mar 180-451727
31 Dec 170-48170
30 Sep 170-491534
30 Jun 170-521437
31 Mar 170-551540
31 Dec 160-581543
30 Sep 160-621646
30 Jun 160-591644
31 Mar 160-551540
31 Dec 150-481333
30 Sep 150-381125
30 Jun 150-33921
31 Mar 150-28818
31 Dec 140-25717
30 Sep 140-24617

Quality Earnings: ATYR is currently unprofitable.

Growing Profit Margin: ATYR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ATYR is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.

Accelerating Growth: Unable to compare ATYR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATYR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: ATYR has a negative Return on Equity (-97.97%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies